Amanda Houlihan

@ahoulihan15

Strategic Communications - Biotech | Rowing Coach | Tweets are my own and reviewed by the group chat

Vrijeme pridruživanja: kolovoz 2018.

Tweetovi

Blokirali ste korisnika/cu @ahoulihan15

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ahoulihan15

  1. 14. sij

    In case you forget where we’ll be this week.

    Poništi
  2. 25. lis 2019.

    Only packing the essentials for the big MacDougall office move.

    Poništi
  3. proslijedio/la je Tweet
    24. lis 2019.

    Dr. Tatiana Novobrantseva just shared what we've been working on at . To catch up on our recent announcements, visit .

    Poništi
  4. 23. lis 2019.

    Thank you to for putting on the Macrophage-directed Therapies Summit. A great first day!

    Poništi
  5. 23. lis 2019.

    For the last event of day one at the Macrophage-directed Therapies Summit Kipp Weiskopf, Whitehead Fellow, and Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, will lead an audience discussion.

    Poništi
  6. 23. lis 2019.

    One more networking break before we head into the final presentation for day one of the Macrophage-directed Therapies Summit.

    Poništi
  7. 23. lis 2019.

    Brandish at thinks we are only scratching the surface. He says there is an "enormous amount of diversity in the myeloid compartment in tumors."

    Poništi
  8. 23. lis 2019.

    Philip Brandish, Senior Principal Scientist, is up next presenting "Therapeutic Approaches & Basic Research on Myeloid Immune Suppression in the Tumor Microenvironment" at the Macrophage-directed Therapies Summit here in .

    Poništi
  9. 23. lis 2019.

    Jennifer Guerriero, Director, Breast Immunology Laboratory is presenting "Targeting Macrophages for Anti-cancer Therapy" at the Macrophage-directed Therapies Summit.

    Poništi
  10. 23. lis 2019.

    's ESM technology targets small molecule drugs to macrophages.

    Prikaži ovu nit
    Poništi
  11. 23. lis 2019.

    Søren Bregenholt, CEO of is up next to present "Regulating Macrophage Polarization to Create a Tumor Suppressive Environment".

    Prikaži ovu nit
    Poništi
  12. 23. lis 2019.

    "In both primary human cell assays and ex vivo tumors PSGL-1 works as a monotherapy and can add to PD1 therapy activity, with potential to expand IO response" - Novobrantseva,

    Prikaži ovu nit
    Poništi
  13. 23. lis 2019.

    Novobrantseva tells the crowd, the "first target we have unblinded is PSGL-1." "PSGL-1 is a cell surface receptor involved in adhesion and immune modulation."

    Prikaži ovu nit
    Poništi
  14. 23. lis 2019.

    When identifying targets Novobrantseva says that uses an all human translational platform and "starts with target discovery from human tumors."

    Poništi
  15. 23. lis 2019.

    Novobrantseva says that "only about a quarter of human cancers respond to t cell engaging immunotherapies." "aims to develop therapies that modulate macrophages."

    Poništi
  16. 23. lis 2019.

    announced their company launch on Monday. tells the story of Verseau's founding and approach to developing targeted therapeutics in this article in .

    Prikaži ovu nit
    Poništi
  17. 23. lis 2019.

    Back from lunch and getting ready for Co-founder and CSO Tatiana Novobrantseva's presentation "Completing the Immunity Cycle by Developing Macrophage Immunotherapies".

    Prikaži ovu nit
    Poništi
  18. 23. lis 2019.

    Taking a quick break for lunch and then it’s back to more presentations on therapies at the Macrophage-directed Therapies Summit.

    Poništi
  19. 23. lis 2019.

    Brie Perell says that , a leading developer and manufacturer of high-quality purified proteins and reagent solutions, is "focusing in on how we can leverage some of these competencies in the macrophage therapeutics space".

    Poništi
  20. 23. lis 2019.

    Brie Perell of is presenting on "Incorporating Novel Tools to Enhance Ex Vivo Cell Manufacturing Workflows" at the Macrophage-directed Therapies Summit

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·